MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%
Sector Heatmap
Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%
ARMP — Armata Pharmaceuticals, Inc. Common Stock
NYSE AmericanArmata Pharmaceuticals, Inc. Common Stock
$3.52
+0.21(+6.34%)
- O
- 3.40
- H
- 3.55
- L
- 3.32
- V
- 123.85K
⏱️ End-of-day dataAs of Oct 2, 2026
ARMP — Latest News & Headlines
8 StoriesArmata Pharmaceuticals (ARMP) Secures $3.7M in Non-Dilutive Funding to Advance Phase 3 Trials - GuruFocus
Armata Pharmaceuticals (ARMP) Secures $3.7M in Non-Dilutive Funding to Advance Phase 3 Trials GuruFocus
Armata Pharmaceuticals Inc (ARMP-A) Stock Price and News - The Globe and Mail
Armata Pharmaceuticals Inc (ARMP-A) Stock Price and News The Globe and Mail
(AMEX: ARMP) Share Price, ARMP Stock News, ARMP Share Price & Updates - Kalkine
(AMEX: ARMP) Share Price, ARMP Stock News, ARMP Share Price & Updates Kalkine
HC Wainwright & Co. reiterates Buy rating on Armata Pharmaceuticals, $15 price target - TradingView
HC Wainwright & Co. reiterates Buy rating on Armata Pharmaceuticals, $15 price target TradingView
Armata secures new U.S. funding for AP-SA02 Phase 3 - The Globe and Mail
Armata secures new U.S. funding for AP-SA02 Phase 3 The Globe and Mail
H.C. Wainwright reiterates Armata Pharmaceuticals stock rating on phage data - Investing.com UK
H.C. Wainwright reiterates Armata Pharmaceuticals stock rating on phage data Investing.com UK
Armata receives $3.7m DoW funding for phase 3 drug trial - Investing.com UK
Armata receives $3.7m DoW funding for phase 3 drug trial Investing.com UK
JonesTrading Reaffirms Their Buy Rating on Armata Pharmaceuticals (ARMP) - The Globe and Mail
JonesTrading Reaffirms Their Buy Rating on Armata Pharmaceuticals (ARMP) The Globe and Mail